Vanderbilt
University Medical Center and Royal Children’s Hospital in Melbourne
look to advance apheresis medicine by leveraging technology and new
patient programs
LAKEWOOD, Colo. - Friday, December 12th 2014 [ME NewsWire]
(BUSINESS
WIRE)-- Vanderbilt University Medical Center and The Royal Children’s
Hospital in Melbourne, Australia (RCH) are driving toward new
possibilities with help from Terumo BCT’s 2014 Advancing Apheresis
Awards. The award program is the first in Terumo BCT’s industry to fund
education grants for the advancement of apheresis. Garrett Booth, MD,
MS, Assistant Professor at Vanderbilt University Medical Center, and
Anthea Greenway, MBBS FRACP FRCPA, Paediatric Haematologist at the RCH,
each received $10,000 for their separate projects.
Booth is
researching the potential of a mobile application to educate patients,
nurses, clinical providers and transfusion medicine trainees to raise
the awareness and understanding of apheresis medicine. Greenway will use
the educational grant funding to establish standard operating
procedures for red blood cell exchange at the RCH and improve
educational support provided to children with Sickle Cell Disease.
KEY FACTS ABOUT THE 2014 ADVANCING APHERESIS AWARDS:
The 2014 Advancing Apheresis Award program was created to support the industry by funding education
Terumo BCT’s Advancing Apheresis Awards is a global grant program
After reviewing the applications, Terumo BCT chose to double its initial commitment and award two $10,000 grants
Vanderbilt University Medical Center will explore the efficacy of a
mobile application to educate patients, nurses, clinical providers and
transfusion medicine trainees about apheresis
The Royal
Children’s Hospital in Melbourne will work to establish new standard
operating procedures for red blood cell exchange at the RCH; The
hospital will also look to provide educational opportunities for
children with Sickle Cell Disease and their families while the children
undergo chronic red blood cell exchanges at the RCH
The grant recipients were chosen by an independent global grant committee:
Zbigniew Szczepiorkowski, MD, PhD, Director, Transfusion Medicine
Service & Cellular Therapy Center, Dartmouth-Hitchcock Medical
Center; American Society for Apheresis (ASFA) Past President; Lead
Contributor to 2010 ASFA Guidelines (U.S.)
Giorgio Baldanzi, MD, Medical Director, HEMOBANCO (Brazil)
Aleksandra Babic, RN, European Institute of Oncology (EIO);
President-Elect, European Group for Bone Marrow Transplant (EBMT) Nurse
Group (Italy)
Ian Lewis, MB, BS, PhD, Head, Acute Leukaemia
Laboratory, Center for Cancer Biology; Medical Manager, Therapeutic
Products Facility (TPF), Royal Adelaide Hospital (Australia)
Terumo BCT had no impact on the committee’s decisions
KEY QUOTES:
Bob Sullivan, Vice President, Therapeutics, Terumo BCT
“The
more we help support apheresis education, the more momentum these
important therapies may have in healthcare. Dr. Booth and Dr. Greenway
have shown their pioneering spirits for greater impacts, and the whole
applicant pool exceeded our expectations. These initiatives could
ultimately have a positive effect on patient care.”
Anthea Greenway, MBBS FRACP FRCPA, Paediatric Haematologist, The Royal Children’s Hospital
“With
this grant, I will work to improve access to educational opportunities
for children and families receiving apheresis at The Royal Children’s
Hospital in Melbourne. New educational opportunities provided during
this essential medical treatment will lead to more knowledgeable
patients along with informed and engaged families.”
Garrett Booth, MD, MS, Assistant Professor at Vanderbilt University Medical Center
“Technology
and education form a powerful combination that can give healthcare
professionals a better understanding of apheresis. Terumo BCT’s award
will help make a mobile application to raise awareness about the
abilities of these amazing therapies.”
About Terumo BCT:
Terumo
BCT, a global leader in blood component, therapeutic apheresis and
cellular technologies, is the only company with the unique combination
of apheresis collections, manual and automated whole blood processing,
and pathogen reduction. We believe in the potential of blood to do even
more for patients than it does today. This belief inspires our
innovation and strengthens our collaboration with customers.
Contacts
Terumo BCT
D.J. Martin, +1-303-239-2060
Global Corporate Communications
press@terumobct.com
Permalink: http://me-newswire.net/news/13095/en

No comments:
Post a Comment